Top-Rated StocksTop-RatedNASDAQ:PLRX Pliant Therapeutics (PLRX) Stock Price, News & Analysis → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free PLRX Stock Alerts $15.27 -0.34 (-2.18%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$15.24▼$15.8750-Day Range$11.81▼$15.6152-Week Range$11.21▼$24.74Volume372,754 shsAverage Volume447,006 shsMarket Capitalization$921.24 millionP/E RatioN/ADividend YieldN/APrice Target$45.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Pliant Therapeutics alerts: Email Address Pliant Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside197.2% Upside$45.38 Price TargetShort InterestBearish12.51% of Shares Sold ShortDividend StrengthN/ASustainability-0.73Upright™ Environmental ScoreNews Sentiment0.30Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.44) to ($3.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.18 out of 5 starsMedical Sector156th out of 919 stocksPharmaceutical Preparations Industry61st out of 422 stocks 4.5 Analyst's Opinion Consensus RatingPliant Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePliant Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pliant Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.51% of the outstanding shares of Pliant Therapeutics have been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 21.8, which indicates bearish sentiment.Change versus previous monthShort interest in Pliant Therapeutics has recently decreased by 0.92%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPliant Therapeutics does not currently pay a dividend.Dividend GrowthPliant Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePliant Therapeutics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Pliant Therapeutics is -0.73. Previous Next 2.4 News and Social Media Coverage News SentimentPliant Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Pliant Therapeutics this week, compared to 3 articles on an average week.Search Interest4 people have searched for PLRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.40% of the stock of Pliant Therapeutics is held by insiders.Percentage Held by Institutions97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pliant Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pliant Therapeutics are expected to decrease in the coming year, from ($3.44) to ($3.71) per share.Price to Book Value per Share RatioPliant Therapeutics has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pliant Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings[URGENT] DO NOT Touch These AI Stocks!Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over?Click here for our #1 AI Stock for 2024 and Beyond About Pliant Therapeutics Stock (NASDAQ:PLRX)Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More PLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLRX Stock News HeadlinesMay 16 at 4:10 AM | markets.businessinsider.comBuy Rating Affirmed for Pliant Therapeutics on Promising Bexotegrast Trial Results in IPFMay 15 at 11:10 PM | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Pliant Therapeutics (PLRX), Trevena (TRVN)May 15 at 1:09 PM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX) and Tenet Healthcare (THC)May 14, 2024 | msn.comPliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In PatientsMay 14, 2024 | globenewswire.comPliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary FibrosisMay 12, 2024 | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Buy" by BrokeragesMay 11, 2024 | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) to Post Q2 2024 Earnings of ($0.82) Per Share, HC Wainwright ForecastsMay 9, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Pliant Therapeutics (NASDAQ:PLRX)May 9, 2024 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) PT Raised to $48.00May 9, 2024 | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Forecasted to Post Q2 2024 Earnings of ($0.81) Per ShareMay 9, 2024 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) Rating Reiterated by Needham & Company LLCMay 9, 2024 | americanbankingnews.comRoyal Bank of Canada Lowers Pliant Therapeutics (NASDAQ:PLRX) Price Target to $45.00May 9, 2024 | americanbankingnews.comCitigroup Lowers Pliant Therapeutics (NASDAQ:PLRX) Price Target to $44.00May 8, 2024 | markets.businessinsider.comPliant Therapeutics: Advancing Trials and Diversifying Pipeline Justify Buy RatingMay 8, 2024 | markets.businessinsider.comBuy Rating for Pliant Therapeutics: Promising Trials and Strategic Shifts Signal Growth PotentialMay 8, 2024 | finance.yahoo.comPliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)May 7, 2024 | markets.businessinsider.comBullish Outlook: Buy Rating on Pliant Therapeutics Amid Strong Clinical Trials and Solid FinancialsMay 7, 2024 | markets.businessinsider.comBuy Rating Justified by Pliant Therapeutics’ Promising Pipeline and Financial PrudenceMay 7, 2024 | msn.comThese Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 EarningsMay 7, 2024 | tmcnet.comPliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™May 7, 2024 | finance.yahoo.comPliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™May 6, 2024 | investorplace.comPLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024May 6, 2024 | globenewswire.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 1, 2024 | globenewswire.comPliant Therapeutics to Participate in Upcoming Investor EventsApril 9, 2024 | investing.comPliant Therapeutics Inc (PLRX)See More Headlines Receive PLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today5/18/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PLRX CUSIPN/A CIK1746473 Webpliantrx.com Phone650-481-6770FaxN/AEmployees158Year FoundedN/APrice Target and Rating Average Stock Price Target$45.38 High Stock Price Target$63.00 Low Stock Price Target$36.00 Potential Upside/Downside+199.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,340,000.00 Net MarginsN/A Pretax Margin-68,847.98% Return on Equity-35.08% Return on Assets-31.78% Debt Debt-to-Equity Ratio0.07 Current Ratio16.12 Quick Ratio16.12 Sales & Book Value Annual Sales$1.58 million Price / Sales583.06 Cash FlowN/A Price / Cash FlowN/A Book Value$7.25 per share Price / Book2.11Miscellaneous Outstanding Shares60,330,000Free Float56,465,000Market Cap$921.24 million OptionableOptionable Beta1.19 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Bernard Coulie M.B.A. (Age 57)M.D., Ph.D., President, CEO & Director Comp: $1.06MDr. Keith Lamont Cummings M.B.A. (Age 47)M.D., Chief Financial Officer Comp: $662.34kMr. Mike Ouimette J.D. (Age 51)General Counsel & Corporate Secretary Comp: $591.05kMr. Johannes P. Hull (Age 49)Chief Business Officer Comp: $631.64kDr. Éric Lefebvre M.D. (Age 60)Chief Medical Officer Comp: $763.49kDr. Rik DerynckScientific Founder & Member of Scientific Advisory BoardMr. Dean Sheppard M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Bill DeGrado Ph.D.Scientific Founder & Member of Scientific Advisory BoardMr. Hal Chapman M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Craig D. MuirInterim Chief Technology OfficerMore ExecutivesKey CompetitorsARS PharmaceuticalsNASDAQ:SPRYABIVAX Société AnonymeNASDAQ:ABVXZentalis PharmaceuticalsNASDAQ:ZNTLImmunomeNASDAQ:IMNMDianthus TherapeuticsNASDAQ:DNTHView All CompetitorsInsiders & InstitutionsRedmile Group LLCBought 400,572 shares on 5/16/2024Ownership: 5.134%California State Teachers Retirement SystemSold 3,227 shares on 5/16/2024Ownership: 0.076%Price T Rowe Associates Inc. MDBought 173,172 shares on 5/15/2024Ownership: 6.562%First Light Asset Management LLCSold 56,783 shares on 5/15/2024Ownership: 5.859%EntryPoint Capital LLCBought 9,992 shares on 5/14/2024Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions PLRX Stock Analysis - Frequently Asked Questions Should I buy or sell Pliant Therapeutics stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PLRX shares. View PLRX analyst ratings or view top-rated stocks. What is Pliant Therapeutics' stock price target for 2024? 9 brokerages have issued 1 year target prices for Pliant Therapeutics' shares. Their PLRX share price targets range from $36.00 to $63.00. On average, they expect the company's stock price to reach $45.38 in the next year. This suggests a possible upside of 197.2% from the stock's current price. View analysts price targets for PLRX or view top-rated stocks among Wall Street analysts. How have PLRX shares performed in 2024? Pliant Therapeutics' stock was trading at $18.11 at the start of the year. Since then, PLRX shares have decreased by 15.7% and is now trading at $15.27. View the best growth stocks for 2024 here. When is Pliant Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our PLRX earnings forecast. How were Pliant Therapeutics' earnings last quarter? Pliant Therapeutics, Inc. (NASDAQ:PLRX) announced its earnings results on Monday, May, 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.76) by $0.02. What ETFs hold Pliant Therapeutics' stock? ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What other stocks do shareholders of Pliant Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN). When did Pliant Therapeutics IPO? Pliant Therapeutics (PLRX) raised $90 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Pliant Therapeutics' major shareholders? Pliant Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (6.56%), First Light Asset Management LLC (5.86%), Vanguard Group Inc. (5.77%), Redmile Group LLC (5.13%), Capital International Investors (2.28%) and Mass General Brigham Inc (0.48%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Hans Hull, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette. View institutional ownership trends. How do I buy shares of Pliant Therapeutics? Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PLRX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBill Clinton Backing Biden Replacement???The Freeport SocietyUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.